HZN-825-302 A multi-center, open-label extension trial to evaluate the efficacy, safety and tolerability of HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis.
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Horizon Therapeutics Ireland DAC
Start Date
May 1, 2024
End Date
February 28, 2027
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Horizon Therapeutics Ireland DAC
Start Date
May 1, 2024
End Date
February 28, 2027